COVID-19 Clinical Trials in China

Abstract

EDITORIAL This article expects to sum up the vital characteristics of registered trials of 2019 novel coronavirus (COVID-19), as far as their spatial and fleeting dispersions, sorts of plan and intercessions, and patient qualities among others. A far reaching search of the enrolled COVID-19 trials has been performed on stages including ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (WHO Chinese Clinical Trials Registry (CHiCTR), Australian Clinical Trials Registry, Britain's National Research Register Current Control Trials (CCT), and Glaxo Smith Kline Register. Preliminaries enlisted at the initial two months of the COVID-19 flare-up are incorporated, without language limitations. For each examination, the enrollment data, study plan, and director data are gathered and summed up.